Core Insights - Liquidia Corp reported mixed results for Q4, with earnings of 15 cents per share, missing the analyst consensus estimate of 17 cents per share, while quarterly sales of $92.021 million exceeded the estimate of $83.634 million [1] Financial Performance - Quarterly earnings: 15 cents per share, below the consensus estimate of 17 cents per share [1] - Quarterly sales: $92.021 million, surpassing the consensus estimate of $83.634 million [1] Market Reaction - Following the earnings announcement, Liquidia shares increased by 4.5%, trading at $36.08 [2] Analyst Ratings and Price Targets - HC Wainwright & Co. analyst Andrew S. Fein maintained a Buy rating and raised the price target from $50 to $55 [4] - Wells Fargo analyst Benjamin Burnett maintained an Overweight rating and increased the price target from $31 to $44 [4] Product Adoption - CEO Dr. Roger Jeffs highlighted the rapid adoption of YUTREPIA® in clinical practice, noting it as one of the top specialty drug launches in the past five years across all therapeutic categories [2]

Core Insights - Liquidia Corporation reported strong financial results for the year ended December 31, 2025, highlighting the successful launch and adoption of YUTREPIA® in clinical practice, which has become one of the top specialty drug launches in recent years [2][5][10] Financial Performance - The company achieved net income of $14.6 million in Q4 2025, marking its second consecutive quarter of profitability, with a positive non-GAAP adjusted EBITDA of $27.3 million [5][10] - Total product sales for the year reached $148.3 million, with $90.1 million generated in the fourth quarter alone [6][10] - Cash and cash equivalents increased to $190.7 million as of December 31, 2025, up from $176.5 million in 2024 [5][10] Revenue Breakdown - Service revenue for the year was $10.0 million, down from $14.0 million in 2024, primarily due to lower sales volumes [7] - Cost of product sales was recorded at $8.8 million for 2025, with no costs associated with product sales in 2024 [8][10] - Research and development expenses decreased by 18% to $39.3 million, while selling, general, and administrative expenses rose by 93% to $157.2 million due to increased personnel and commercial expenses [12][13] Market Adoption and Growth Strategy - YUTREPIA has seen over 3,600 unique prescriptions and has treated more than 2,900 patients since its launch in June 2025, with a strong prescription-to-start conversion rate above 85% [10][11] - The company plans to deepen prescriber adoption, expand its sales force, and advance its L606 program into pivotal trials, all funded from operations [3][10] Product Information - YUTREPIA is an inhaled dry-powder formulation of treprostinil, indicated for treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) [17] - L606 is an investigational extended-release formulation of treprostinil, currently in clinical evaluation for PAH and PH-ILD [18]